References
- Donati MB. Cancer and thrombosis from phlegmasia alba dolens to transgenic mice. Thromb Haemost 1995;74:278–281.
- Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 2005;6:401–410.
- Sorensen H, Steffensen F, Olsen J, Nielsen G. The risk of a diagnosis of cancer after primary deep venous thrombosis or embolism pulmonary. N Engl J Med 1998;338:1169–1173.
- Hillen HF. Thrombosis in cancer patients. Ann Oncol 2000; 11 (Suppl 3) :273–276.
- Rickles F, Levine M, Edwards R. Haemostatic alterations in cancer patients. Cancer Metastsis Rev 1992;11:208–213.
- Donati MB, Falanga A. Pathogenetic mechanism of throm-bosis in malignancy. Acta Haematol 2001;106:18–24.
- Falanga A, Rickles F. Pathophysiology of the thrombofilic state in cancer patients. Semin Thromb Haemost 1999;25:173–182.
- Falanga A. Tumor cells prothrombotic properties. Haemo-stasis 2001;31:1–4.
- Eilestsen K, Osterud B. Tissue factor: (patho)physiology and cellular biology. Blood Coagul Fibrinolysis 2004;15:521–538.
- Yu J, Rak J. Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells. J Thromb Haemost 2004;2:2065–2067.
- Gale A, Gordon S. Update on tumor cell procoagulant factors. Acta Haematol 2001;106:25–32.
- Gordon S, Cross B. An enzyme-linked immunosorbent assay for cancer procoagulant and its potential as a new marker. Cancer Res 1994;50:6229–6234.
- Mielicki W, Tenderenda M. Activation of blood coagulation and the activity of cancer procoagulant breast cancer patients. Cancer Lett 1999;146:61–66.
- Zuchella M, Pacchiarini L, Tacconi F, Saporiti A, Griganani G. Different expression of procoagulant activity in human cancer cells cultured in vitro or in cells isolated from human tumor tissues. Thromb Haemost 1993;69:335–338.
- Gordon S, Benson B. Analysis of serum cancer procoagulant activity and its possible use as a tumor marker. Thromb Res 1989;56:431–440.
- Golino P. The inhibition of tissue factor: Factor VII pathway. Thromb Res 2002;95:257–265.
- Gianni M, Norio P, Tenao M. Effects of dexamethasone on proinflammatory cytokine expression, cell growth and matu-ration during granulocytic differention of APL cells. Eur Cytokine Network 1995;6:157–165.
- Colucci M, Delaini F, De Bellis Vitti G, Locat D, Poggi A, Donato MB. Warfarin inhibits both procoagulant activity and metastatic capacity of Lewis lung carcinoma cells. Role of vitamin K deficiency. Biochem Pharmacol 1993;32:1689–1691.
- Hau C, Simrit P, Jun W. Pathogenesis of increased risk of thrombosis in cancer. Semin Thromb Haemost 2003;29: 283–290.